Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth - 2Israeli lawmakers pass bill reviving death penalty for terrorists
- 3Share your pick for the riding area that characterizes your surf undertakings!
- 4Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts
- 5JW Marriott Tokyo: an elegant retreat amid whirlwind of the city
- Looking for under-the-radar adventures? Try Norway's Vesterålen
- Far-right AfD invited back to Munich Security Conference in 2026
- 5 Language Learning Applications
- Artemis 2 astronauts reveal adorable zero-g indicator 'Rise' | Space photo of the day for March 31, 2026
- The most effective method to Involve Handshakes for Compromise and Compromise
- Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- Display of Netanyahu's severed head 'incites public to murder PM', Likud says in official complaint
- Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
